Primary aldosteronism (PA) is a clinical condition characterized by suppressedplasma renin activity (PRA), elevated plasma aldosterone concentration (PAC), and hypertension with or without hypokalemia, which are commonly resulting from aldosterone hypersecretion by lesions in the adrenal glands [1]. PA patients are at a high risk ofcardiovascular, cerebrovascular, and metabolic complications [2,3],underscoring the importance of effective control of aldosterone hypersecretion.